Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | VIR |
---|---|---|
09:32 ET | 165030 | 9.015 |
09:34 ET | 3475 | 8.93 |
09:36 ET | 577 | 8.905 |
09:38 ET | 1659 | 8.92 |
09:39 ET | 18894 | 8.9239 |
09:41 ET | 6716 | 8.96 |
09:43 ET | 10712 | 8.96 |
09:45 ET | 3780 | 8.92 |
09:48 ET | 2882 | 8.93 |
09:50 ET | 4947 | 8.955 |
09:52 ET | 5773 | 8.93 |
09:54 ET | 9301 | 8.89 |
09:56 ET | 9966 | 8.88 |
09:57 ET | 2651 | 8.87 |
09:59 ET | 4882 | 8.9 |
10:01 ET | 8976 | 8.9 |
10:03 ET | 10106 | 8.9 |
10:06 ET | 3654 | 8.905 |
10:08 ET | 2300 | 8.9 |
10:10 ET | 200 | 8.905 |
10:12 ET | 2400 | 8.9 |
10:14 ET | 3310 | 8.88 |
10:15 ET | 900 | 8.885 |
10:17 ET | 700 | 8.9 |
10:19 ET | 1500 | 8.89 |
10:24 ET | 300 | 8.89 |
10:26 ET | 4194 | 8.89 |
10:28 ET | 1410 | 8.905 |
10:30 ET | 1849 | 8.9 |
10:32 ET | 805 | 8.9084 |
10:33 ET | 760 | 8.89 |
10:35 ET | 702 | 8.9 |
10:37 ET | 600 | 8.89 |
10:39 ET | 13154 | 8.86 |
10:42 ET | 700 | 8.855 |
10:44 ET | 911 | 8.87 |
10:46 ET | 450 | 8.89 |
10:48 ET | 967 | 8.88 |
10:50 ET | 300 | 8.89 |
10:51 ET | 100 | 8.9 |
10:53 ET | 200 | 8.89 |
10:55 ET | 2523 | 8.88 |
10:57 ET | 600 | 8.87 |
11:00 ET | 1300 | 8.87 |
11:02 ET | 600 | 8.87 |
11:04 ET | 100 | 8.87 |
11:06 ET | 2350 | 8.86 |
11:08 ET | 300 | 8.86 |
11:09 ET | 1276 | 8.84 |
11:11 ET | 4400 | 8.845 |
11:13 ET | 100 | 8.85 |
11:15 ET | 1786 | 8.8544 |
11:18 ET | 2789 | 8.87 |
11:20 ET | 790 | 8.88 |
11:22 ET | 200 | 8.87 |
11:24 ET | 100 | 8.875 |
11:26 ET | 1600 | 8.9 |
11:27 ET | 4228 | 8.885 |
11:29 ET | 100 | 8.87 |
11:31 ET | 1463 | 8.88 |
11:33 ET | 934 | 8.89 |
11:36 ET | 143 | 8.89 |
11:38 ET | 485 | 8.89 |
11:40 ET | 970 | 8.88 |
11:44 ET | 500 | 8.86 |
11:45 ET | 1300 | 8.85 |
11:47 ET | 700 | 8.87 |
11:49 ET | 381 | 8.88 |
11:51 ET | 1586 | 8.87 |
11:54 ET | 3093 | 8.88 |
11:56 ET | 1342 | 8.88 |
11:58 ET | 1215 | 8.9 |
12:00 ET | 1600 | 8.89 |
12:02 ET | 785 | 8.9 |
12:03 ET | 815 | 8.9279 |
12:05 ET | 348 | 8.93 |
12:07 ET | 2115 | 8.91 |
12:09 ET | 974 | 8.911 |
12:12 ET | 1900 | 8.9035 |
12:14 ET | 300 | 8.92 |
12:16 ET | 200 | 8.91 |
12:18 ET | 1666 | 8.89 |
12:20 ET | 829 | 8.9 |
12:21 ET | 2900 | 8.92 |
12:23 ET | 400 | 8.91 |
12:25 ET | 850 | 8.9185 |
12:27 ET | 2370 | 8.92 |
12:30 ET | 300 | 8.92 |
12:32 ET | 1600 | 8.93 |
12:34 ET | 2407 | 8.93 |
12:36 ET | 400 | 8.93 |
12:39 ET | 1693 | 8.9408 |
12:41 ET | 1163 | 8.93 |
12:43 ET | 400 | 8.93 |
12:45 ET | 803 | 8.93 |
12:48 ET | 300 | 8.93 |
12:50 ET | 2922 | 8.915 |
12:52 ET | 800 | 8.91 |
12:54 ET | 400 | 8.915 |
12:56 ET | 1922 | 8.92 |
12:57 ET | 777 | 8.93 |
12:59 ET | 4987 | 8.9 |
01:01 ET | 1464 | 8.88 |
01:03 ET | 1150 | 8.9 |
01:06 ET | 700 | 8.9 |
01:08 ET | 700 | 8.905 |
01:10 ET | 1378 | 8.91 |
01:12 ET | 1016 | 8.9 |
01:14 ET | 2229 | 8.89 |
01:15 ET | 1348 | 8.895 |
01:17 ET | 500 | 8.895 |
01:19 ET | 1342 | 8.9 |
01:21 ET | 2963 | 8.89 |
01:24 ET | 100 | 8.89 |
01:28 ET | 2506 | 8.9 |
01:30 ET | 1202 | 8.9 |
01:32 ET | 8909 | 8.92 |
01:33 ET | 4795 | 8.91 |
01:35 ET | 2142 | 8.91 |
01:37 ET | 719 | 8.91 |
01:39 ET | 1783 | 8.9 |
01:42 ET | 1748 | 8.9 |
01:44 ET | 650 | 8.9 |
01:46 ET | 1925 | 8.89 |
01:48 ET | 2605 | 8.91 |
01:50 ET | 1428 | 8.93 |
01:51 ET | 9207 | 8.96 |
01:53 ET | 6796 | 8.955 |
01:55 ET | 700 | 8.97 |
01:57 ET | 2194 | 8.94 |
02:00 ET | 3723 | 8.94 |
02:02 ET | 189180 | 9.03 |
02:04 ET | 12512 | 9.065 |
02:06 ET | 23920 | 9.0039 |
02:08 ET | 2882 | 9.01 |
02:09 ET | 1407 | 9.02 |
02:11 ET | 3660 | 9 |
02:13 ET | 456 | 9 |
02:15 ET | 1912 | 9.01 |
02:18 ET | 3425 | 9 |
02:20 ET | 10963 | 8.99 |
02:22 ET | 200 | 8.99 |
02:24 ET | 1399738 | 9.01 |
02:26 ET | 800 | 9.05 |
02:27 ET | 1521 | 9.1 |
02:29 ET | 16942 | 9.1 |
02:31 ET | 2477 | 9.07 |
02:33 ET | 9801 | 9.055 |
02:36 ET | 17486 | 9.075 |
02:38 ET | 12156 | 9.075 |
02:40 ET | 5636 | 9.11 |
02:42 ET | 23616 | 9.1 |
02:44 ET | 3592 | 9.102 |
02:45 ET | 2310 | 9.17 |
02:47 ET | 9659 | 9.15 |
02:49 ET | 3317 | 9.16 |
02:51 ET | 6391 | 9.125 |
02:54 ET | 9698 | 9.088 |
02:56 ET | 6433 | 9.085 |
02:58 ET | 5670 | 9.07 |
03:00 ET | 5351 | 9.09 |
03:02 ET | 4570 | 9.075 |
03:03 ET | 9237 | 9.07 |
03:05 ET | 1052 | 9.07 |
03:07 ET | 1589 | 9.06 |
03:09 ET | 3751 | 9.05 |
03:12 ET | 8614 | 9.07 |
03:14 ET | 5145 | 9.09 |
03:16 ET | 5097 | 9.105 |
03:18 ET | 1985 | 9.1 |
03:20 ET | 9840 | 9.105 |
03:21 ET | 12853 | 9.07 |
03:23 ET | 3783 | 9.095 |
03:25 ET | 956 | 9.085 |
03:27 ET | 9048 | 9.09 |
03:30 ET | 7900 | 9.1 |
03:32 ET | 7798 | 9.01 |
03:34 ET | 11496 | 9 |
03:36 ET | 10519 | 9 |
03:38 ET | 7959 | 9.01 |
03:39 ET | 7304 | 9.01 |
03:41 ET | 9032 | 9.01 |
03:43 ET | 10219 | 9.015 |
03:45 ET | 11193 | 9.015 |
03:48 ET | 20373 | 9.03 |
03:50 ET | 13362 | 9.03 |
03:52 ET | 20275 | 9.0101 |
03:54 ET | 34966 | 9.05 |
03:56 ET | 41443 | 9.125 |
03:57 ET | 19629 | 9.125 |
03:59 ET | 23236 | 9.14 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Vir Biotechnology Inc | 1.2B | -2.3x | --- |
Nurix Therapeutics Inc | 1.3B | -8.0x | --- |
Prothena Corporation PLC | 1.2B | -6.6x | --- |
Immatics NV | 1.3B | -11.9x | --- |
Silence Therapeutics PLC | 916.9M | -16.7x | --- |
Arcutis Biotherapeutics Inc | 982.8M | -2.9x | --- |
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.2B |
---|---|
Revenue (TTM) | $79.6M |
Shares Outstanding | 136.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.48 |
EPS | $-4.01 |
Book Value | $11.80 |
P/E Ratio | -2.3x |
Price/Sales (TTM) | 15.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -780.18% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.